drugset / Trial / NCT04157114
MAP4343 Treatment for Alcohol Use Disorder
Phase 2
Withdrawn
The Scripps Research Institute
Mapreg · collabNational Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2, single-site, randomized, double-blind, placebo-controlled, proof-of-concept (POC) study involving 6 weeks of MAP4343 in conjunction with 6 weeks of manual-guided counseling, with 2 follow-up visits at 1 week and 1 month post-treatment.
Timeline
- Start
- 2021-12
- Primary completion
- 2022-12
- Completion
- 2022-12
Outcome
Outcome not reported
Stopped: “The FDA requested Mapreg conduct an alcohol interaction study which was not feasible due to the COVID-19 pandemic.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MAP4343 | Unknown | — | Oral |